Nasdaq Announces Annual Changes to Nasdaq Biotechnology Index
Nasdaq recently announced the results of the annual re-ranking of the Nasdaq Biotechnology Index. The re-ranking is effective prior to market open on December 24, 2018. There will be 224 companies in the index, including 60 new additions.
The Nasdaq Biotechnology Index (Nasdaq: NBI) is designed to track the performance of a set of securities listed on Nasdaq that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). Between 1/21/03 and 12/14/18, the index had a cumulative return of 522%, and an annualized return of 12%.
In 2018, Nasdaq led in U.S. listings with a healthcare initial public offering (IPO) win rate of 83%. When considering our long-term partnership, healthcare companies strongly benefit from Nasdaq’s superior market model, leading market intelligence and advisory tools, visibility platform, and index inclusion opportunities, including the Nasdaq Biotech Index and Nasdaq-100 Index. Markedly, companies can benefit from our more predictable all-inclusive fee structure that aligns with the growth and success of their businesses.
Nasdaq also continues to be a leader in biotechnology listings, including initial public offerings in the biotechnology and pharmaceutical sectors. In 2018, we proudly listed 94% of biotech IPOs, including Moderna who raised over $600 million—the largest ever venture-backed IPO. Nasdaq is proud to partner with healthcare companies of all sizes, including supporting some of the earliest stage healthcare companies as they transform medicine and help to improve the lives of patients around the world.
If you have any questions, including how to leverage inclusion in the index, please do not hesitate to contact me at jordan.saxe@nasdaq.com
Jordan B. Saxe is Senior Managing Director, Listing Services at Nasdaq. He is responsible for leading business development efforts in the healthcare sector, and brings over thirteen years of experience within the exchange field. He has advised over 200 IPOs and has worked closely with venture capital, private equity and investment firms to educate them on the liquidity options Nasdaq can provide. He holds a B.S. in Business Administration from the University of Vermont.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.